SALARIUS PHARMACEUTICALS SLRX 深 沪
已收盘 01-07 16:00:00 美东时间
0.84
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.84
- 总市值 79.35万
- 52周最高 44.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.5148
- 委 比 0.00%
- 总股本 94.46万
- 历史最高 44445.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.5148
- 每 手 1
- 风险率 7.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Salarius Pharmaceuticals Changes Corporate Name To Decoy Therapeutics, Nasdaq Ticker To DCOY, Effective Jan. 8
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market under the ticker symbol
01-07 21:46
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
<p>Decoy Therapeutics Inc. will change its name from Salarius Pharmaceuticals and begin trading under the ticker symbol DCOY on January 8, 2026. The company focuses on developing peptide-conjugate therapeutics using an AI-driven platform to simplify drug development. Its 2026 plan includes advancing an antiviral program into clinical trials, expanding its pipeline, and pursuing partnerships. The company aims to target respiratory viruses and GI c...
01-07 13:45
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Salarius Pharmaceuticals, Inc. has adjourned its 2025 Annual Meeting of Stockholders due to insufficient voter representation, with only 30% of shares voted. The meeting, originally held on December 19, 2025, will reconvene on December 31, 2025, at 10:00 a.m. Central Time, continuing virtually via live webcast. Shareholders of record as of October 24, 2025, are encouraged to vote promptly via the Internet at www.proxyvote.com, by phone at 1-800-6...
2025-12-19 16:12
Salarius Pharmaceuticals To Rebrand As Decoy Therapeutics Following Combination, Changes NASDAQ Ticker Symbol To DCOY
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker "DCOY" effective in early January 2026Company to focus on advancing lead antiviral programs,
2025-12-18 20:52
Salarius' Decoy Therapeutics Announces Collaboration To Conduct In Vitro Testing Of Decoy's Peptide Conjugate Fusion Inhibitors Across Several Influenza Strains Including H5N1 Avian Flu
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting
2025-12-01 21:03
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Decoy Therapeutics, a subsidiary of Salarius Pharmaceuticals, is developing influenza fusion inhibitors using its IMP3ACT platform, showing strong binding affinity to viral targets. Collaborating with Texas Biomed, they conduct in vitro testing across influenza strains, including H5N1. The IMP3ACT platform leverages AI and rapid synthesis to design broad-spectrum antivirals targeting influenza, COVID, and RSV. Salarius aims to address global resp...
2025-12-01 13:00
Salarius Pharma Cites Error On S&P CapIQ Platform; Reiterates Active Nasdaq Trading Under SLRX Ticker
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under
2025-11-20 03:47
3 Penny Stocks to Watch Now, 11/13/25
Leap Therapeutics, Amaze Holdings, and Salarius Pharmaceuticals are the 3...
2025-11-13 23:02
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Salarius Pharmaceuticals and Decoy Therapeutics have completed their strategic merger, with the combined company focused on advancing Decoy’s peptide conjugate therapeutics via its IMP3ACT platform. The merger provides the company with $14 million in pro forma cash after the merger and recent public offering. Decoy’s technology enables rapid drug design and manufacturing, targeting unmet medical needs in areas like respiratory infectious diseases...
2025-11-13 13:45
Salarius stock slides after pricing $7M offering
Salarius Pharmaceuticals (SLRX) has priced an offering to raise $7M in gross proceeds. The offering includes 2.5M common shares and pre-funded warrants to purchase 2.15M shares, each paired with Serie...
2025-11-12 01:02
